Histopathological Types of Papillary Thyroid Carcinoma: Clinicopathologic Study
DOI:
https://doi.org/10.3889/oamjms.2022.8059Keywords:
Papillary thyroid carcinoma, High malignant potential, Papillary microcarcinoma variant, Extrathyroid extensionAbstract
BACKGROUND: Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma that represents a set of characteristic of nuclear features in which the diagnosis is depend.
AIM: The study aimed to review different variants of PTC which has different malignant potential in correlation with many prognostic and clinical factors in Iraq.
PATIENTS AND METHODS: Paraffin blocks of 227 cases of PTC were selected, subtyped, and grouped according to the malignant potential. The prognostic and clinical factors were studied.
RESULTS: The mean age was (39.29 ± 12.17) years, with female predominance (86.3%), where (55.5%) of them below 40 years, conventional variant was most common (40.1%), followed by papillary microcarcinoma variant, 197 cases (86.8%) were classified as low to intermediate malignant potential, and 30 cases (13.2%) were classified as high malignant potential. On comparison, among the tumor stages, tumor focality, native capsular invasion, lymph nodes involvement, presence or absence of vascular invasion, extrathyroid extension, and distant metastasis, there is no significant correlation between them, whereas with the tumor size, there is significant correlation between them (p =< 0.05).
CONCLUSION: Conventional type followed by micropapillary type is most common. The mean age in Iraqi patients is lower than other countries for PTC. There is no significant association regarding prognostic factors between low to intermediate malignant potential variants and high malignant potential variants with exception of tumor diameter.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023-9. https://doi.org/10.1001/jamaoncol.2016.0386 PMid:27078145 DOI: https://doi.org/10.1001/jamaoncol.2016.0386
Hussain AM, Lafta RK. Cancer Trends in Iraq 2000-2016. Oman Med J. 2021;36(1):e219. https://doi.org/10.5001/omj.2021.18 PMid:33552559 DOI: https://doi.org/10.5001/omj.2021.18
Lloyd RV, Osamura RY, Klöppel G, Rosai J. Who Classification of Endocrine Organs. 4th ed. Lyon, France: IARC; 2017. Available from: https://www.iarc.who.int/news-events/who-classification-of-tumours-of-endocrine-organs [Last accessed on 2021 Nov 20].
Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011;5(1):51-6. https://doi.org/10.1007/s12105-010-0236-9 PMid:21221869 DOI: https://doi.org/10.1007/s12105-010-0236-9
Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212. https://doi.org/10.1155/2013/965212 PMid:23737785 DOI: https://doi.org/10.1155/2013/965212
Albi E, Cataldi S, Lazzarini A, Codini M, Beccari T, Ambesi-Impiombato FS, et al. Radiation and thyroid cancer. Int J Mol Sci. 2017;18(5):911. https://doi.org/10.3390/ijms18050911 PMid:28445397 DOI: https://doi.org/10.3390/ijms18050911
Bomeli SR, LeBeau SO, Ferris RL. Evaluation of a thyroid nodule. Otolaryngol Clin North Am. 2010;43(2):229-38, 7. https://doi.org/10.1016/j.otc.2010.01.002 PMid:20510711 DOI: https://doi.org/10.1016/j.otc.2010.01.002
Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A. Overall survival of papillary thyroid carcinoma patients: A single-institution long-term follow-up of 5897 patients. World J Surg. 2018;42(3):615-22. https://doi.org/10.1007/s00268-018-4479-z PMid:29349484 DOI: https://doi.org/10.1007/s00268-018-4479-z
Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015;8(1):30-40. PMid:25964831
Singhal S, Sippel RS, Chen H, Schneider DF. Distinguishing classical papillary thyroid microcancers from follicular-variant microcancers. J Surg Res. 2014;190(1):151-6. https://doi.org/10.1016/j.jss.2014.03.032 PMid:24735716 DOI: https://doi.org/10.1016/j.jss.2014.03.032
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. https://doi.org/10.3322/caac.21442 PMid:29313949 DOI: https://doi.org/10.3322/caac.21442
Cho JS, Yoon JH, Park MH, Shin SH, Jegal YJ, Lee JS, et al. Age and prognosis of papillary thyroid carcinoma: Retrospective stratification into three groups. J Korean Surg Soc. 2012;83(5):259-66. https://doi.org/10.4174/jkss.2012.83.5.259 PMid:23166884 DOI: https://doi.org/10.4174/jkss.2012.83.5.259
Ng SC, Kuo SF, Chen ST, Hsueh C, Huang BY, Lin JD. Therapeutic outcomes of patients with multifocal papillary thyroid microcarcinomas and larger tumors. Int J Endocrinol. 2017;2017:4208178. https://doi.org/10.1155/2017/4208178 PMid:28642790 DOI: https://doi.org/10.1155/2017/4208178
Selek A, Cetinarslan B, Tarkun I, Canturk Z, Ustuner B, Akyay Z. Thyroid autoimmunity: Is really associated with papillary thyroid carcinoma? Eur Arch Otorhinolaryngol. 2017;274(3):1677-81. https://doi.org/10.1007/s00405-016-4414-6 PMid:27933384 DOI: https://doi.org/10.1007/s00405-016-4414-6
Consorti F, Loponte M, Milazzo F, Potasso L, Antonaci A. Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur Surg Res. 2010;45(3-4):333-7. https://doi.org/10.1159/000320954 PMid:21051899 DOI: https://doi.org/10.1159/000320954
Lubitz CC, Economopoulos KP, Pawlak AC, Lynch K, Dias- Santagata D, Faquin WC, et al. Hobnail variant of papillary thyroid carcinoma: An institutional case series and molecular profile. Thyroid. 2014;24(6):958-65. https://doi.org/10.1089/thy.2013.0573 PMid:24417340 DOI: https://doi.org/10.1089/thy.2013.0573
Maksimovic S, Jakovljevic B, Gojkovic Z. Lymph node metastases papillary thyroid carcinoma and their importance in recurrence of disease. Med Arch. 2018;72(2):108-11. https://doi.org/10.5455/medarh.2018.72.108-111 PMid:29736098 DOI: https://doi.org/10.5455/medarh.2018.72.108-111
Lee J, Soh EY. Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis, clinical outcomes and prognostic factors. Ann Surg. 2010;251(1):114-9. https://doi.org/10.1097/SLA.0b013e3181b7faf6 PMid:19779325 DOI: https://doi.org/10.1097/SLA.0b013e3181b7faf6
Khan U, Al Afif A, Aldaihani A, MacKay C, Rigby MH, Rajaraman M, et al. Patient and tumor factors contributing to distant metastasis in well-differentiated thyroid cancer: A retrospective cohort study. J Otolaryngol Head Neck Surg. 2020;49(1):78. https://doi.org/10.1186/s40463-020-00469-8 PMid:33198797 DOI: https://doi.org/10.1186/s40463-020-00469-8
Furlan JC, Bedard YC, Rosen IB. Significance of tumor capsular invasion in well-differentiated thyroid carcinomas. Am Surg. 2007;73(5):484-91. PMid:17521005 DOI: https://doi.org/10.1177/000313480707300514
Wreesmann VB, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, et al. Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. Thyroid. 2015;25(5):503-8. https://doi.org/10.1089/thy.2015.0052 PMid:25748079 DOI: https://doi.org/10.1089/thy.2015.0052
Furlan JC, Bedard YC, Rosen IB. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. J Am Coll Surg. 2004;198(3):341-8. https://doi.org/10.1016/j.jamcollsurg.2003.11.012 PMid:14992733 DOI: https://doi.org/10.1016/j.jamcollsurg.2003.11.012
Nixon IJ, Ganly I, Patel S, Palmer FL, Whitcher MM, Tuttle RM, et al. The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery. 2011;150(6):1242-9. https://doi.org/10.1016/j.surg.2011.09.007 PMid:22136847 DOI: https://doi.org/10.1016/j.surg.2011.09.007
Hu A, Clark J, Payne RJ, Eski S, Walfish PG, Freeman JL. Extrathyroidal extension in well-differentiated thyroid cancer: Macroscopic vs microscopic as a predictor of outcome. Arch Otolaryngol Head Neck Surg. 2007;133(7):644-9. https://doi.org/10.1001/archotol.133.7.644 PMid:17638775 DOI: https://doi.org/10.1001/archotol.133.7.644
Edge SB, Compton CC. The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4. https://doi.org/10.1245/s10434-010-0985-4 PMid:20180029 DOI: https://doi.org/10.1245/s10434-010-0985-4
Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375-81; discussion 381-4. https://doi.org/10.1097/SLA.0b013e31814697d9 PMid:17717441 DOI: https://doi.org/10.1097/SLA.0b013e31814697d9
Zhang TT, Li CF, Wen SS, Huang DZ, Sun GH, Zhu YX, et al. Effects of tumor size on prognosis in differentiated thyroid carcinoma smaller than 2 cm. Oncol Lett. 2019;17(5):4229-36. https://doi.org/10.3892/ol.2019.10088 PMid:30944617 DOI: https://doi.org/10.3892/ol.2019.10088
Tran B, Roshan D, Abraham E, Wang L, Garibotto N, Wykes J, et al. The prognostic impact of tumor size in papillary thyroid carcinoma is modified by age. Thyroid. 2018;28(8):991-6. https://doi.org/10.1089/thy.2017.060 PMid:29921174 DOI: https://doi.org/10.1089/thy.2017.0607
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9. https://doi.org/10.3322/caac.21388 PMid:28094848 DOI: https://doi.org/10.3322/caac.21388
Downloads
Published
How to Cite
License
Copyright (c) 2022 Zainab Khalid Almukhtar (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
